ARISAPH PHARMACEUTICALS, INC.

Basic Information

100 HIGH STREET
BOSTON, MA, 02110-2321

Company Profile

n/a

Additional Details

Field Value
DUNS: 608549478
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma

    Amount: $232,852.00

    DESCRIPTION (provided by applicant): In the United States, around 76,250 new cases of melanoma and 9,180 melanoma-related deaths are predicted for 2012. With the therapeutic options currently availabl ...

    STTR Phase I 2013 Department of Health and Human Services
  2. A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors

    Amount: $266,641.00

    DESCRIPTION (provided by applicant): In the United States colorectal cancer (CRC) is the third leading cause of cancer mortality. Surgery is the primary treatment for early stage CRC; but adjuvant the ...

    STTR Phase I 2012 Department of Health and Human Services
  3. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    Amount: $245,638.00

    DESCRIPTION (provided by applicant): Cancer is America's second leading cause of death. Many approved cancer drugs, such as bortezomib (Velcade), are cytotoxic agents that kill normal cells as we ...

    STTR Phase I 2011 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government